 Michael Mohning
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 4 | 2025 | 654 | 1.050 |
Why?
| | Asthma, Exercise-Induced | 1 | 2024 | 8 | 0.910 |
Why?
| | Bronchoconstriction | 1 | 2024 | 32 | 0.900 |
Why?
| | Spirometry | 1 | 2025 | 281 | 0.890 |
Why?
| | Lung Diseases, Interstitial | 3 | 2025 | 636 | 0.880 |
Why?
| | Cough | 2 | 2015 | 122 | 0.840 |
Why?
| | Exercise Test | 2 | 2024 | 625 | 0.790 |
Why?
| | Dyspnea | 2 | 2015 | 254 | 0.780 |
Why?
| | Oxygen Consumption | 2 | 2022 | 695 | 0.640 |
Why?
| | Acute Lung Injury | 3 | 2017 | 287 | 0.640 |
Why?
| | Lung Diseases | 1 | 2025 | 767 | 0.590 |
Why?
| | Tomography, X-Ray Computed | 4 | 2025 | 2667 | 0.590 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2017 | 45 | 0.550 |
Why?
| | Cell-Derived Microparticles | 1 | 2017 | 71 | 0.510 |
Why?
| | Alveolitis, Extrinsic Allergic | 3 | 2023 | 97 | 0.480 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 234 | 0.480 |
Why?
| | Phagocytosis | 1 | 2017 | 379 | 0.480 |
Why?
| | Macrophages, Alveolar | 1 | 2017 | 391 | 0.440 |
Why?
| | Proto-Oncogene Proteins | 1 | 2017 | 647 | 0.430 |
Why?
| | Lung | 4 | 2019 | 4052 | 0.330 |
Why?
| | Vital Capacity | 3 | 2025 | 311 | 0.320 |
Why?
| | Pulmonary Fibrosis | 2 | 2025 | 399 | 0.290 |
Why?
| | Inflammation | 1 | 2017 | 2834 | 0.250 |
Why?
| | Bronchial Provocation Tests | 1 | 2024 | 51 | 0.230 |
Why?
| | Forced Expiratory Volume | 1 | 2025 | 531 | 0.210 |
Why?
| | Diagnosis, Differential | 2 | 2019 | 1481 | 0.200 |
Why?
| | Respiratory Function Tests | 1 | 2024 | 595 | 0.200 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2025 | 652 | 0.190 |
Why?
| | Exercise | 2 | 2024 | 2043 | 0.180 |
Why?
| | Asthma | 1 | 2015 | 2282 | 0.180 |
Why?
| | Extracellular Traps | 1 | 2021 | 53 | 0.180 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2021 | 115 | 0.170 |
Why?
| | Lactic Acid | 1 | 2022 | 305 | 0.160 |
Why?
| | Macrophages | 2 | 2018 | 1544 | 0.160 |
Why?
| | Sputum | 1 | 2021 | 311 | 0.160 |
Why?
| | Radiologists | 1 | 2019 | 50 | 0.150 |
Why?
| | Bleomycin | 2 | 2018 | 247 | 0.150 |
Why?
| | Fatty Acids | 1 | 2022 | 442 | 0.150 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 98 | 0.150 |
Why?
| | Fibrosis | 1 | 2021 | 551 | 0.150 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2018 | 22 | 0.140 |
Why?
| | Humans | 14 | 2025 | 136764 | 0.140 |
Why?
| | CD11 Antigens | 1 | 2018 | 30 | 0.140 |
Why?
| | Cause of Death | 1 | 2019 | 430 | 0.130 |
Why?
| | Prognosis | 1 | 2025 | 4013 | 0.130 |
Why?
| | Mortality | 1 | 2019 | 359 | 0.130 |
Why?
| | CD11b Antigen | 1 | 2016 | 61 | 0.130 |
Why?
| | Gene Deletion | 1 | 2018 | 389 | 0.130 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 61 | 0.120 |
Why?
| | Phagocytes | 1 | 2016 | 100 | 0.120 |
Why?
| | Auscultation | 1 | 2015 | 4 | 0.120 |
Why?
| | Mice, Inbred C57BL | 4 | 2017 | 5735 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2015 | 167 | 0.110 |
Why?
| | Antigens, CD | 1 | 2016 | 521 | 0.100 |
Why?
| | Neovascularization, Physiologic | 1 | 2014 | 178 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1167 | 0.100 |
Why?
| | Regeneration | 1 | 2014 | 195 | 0.100 |
Why?
| | Middle Aged | 6 | 2025 | 33228 | 0.090 |
Why?
| | Male | 9 | 2025 | 67309 | 0.090 |
Why?
| | Mice, Knockout | 1 | 2017 | 3003 | 0.080 |
Why?
| | Apoptosis | 1 | 2017 | 2551 | 0.070 |
Why?
| | Female | 10 | 2025 | 72787 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2822 | 0.070 |
Why?
| | Animals | 7 | 2018 | 36823 | 0.060 |
Why?
| | Mice | 4 | 2018 | 17733 | 0.060 |
Why?
| | Adenoviridae Infections | 1 | 2005 | 17 | 0.060 |
Why?
| | Enterotoxins | 1 | 2005 | 87 | 0.060 |
Why?
| | Signal Transduction | 1 | 2017 | 5075 | 0.050 |
Why?
| | Intracellular Fluid | 1 | 2003 | 27 | 0.050 |
Why?
| | Bronchoscopy | 1 | 2025 | 223 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 545 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2003 | 216 | 0.050 |
Why?
| | Th2 Cells | 1 | 2003 | 176 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2003 | 226 | 0.050 |
Why?
| | Sulfhydryl Compounds | 1 | 2003 | 189 | 0.050 |
Why?
| | Pyridones | 1 | 2023 | 168 | 0.050 |
Why?
| | Pneumonia | 2 | 2017 | 635 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 790 | 0.040 |
Why?
| | Occupations | 1 | 2019 | 48 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2003 | 712 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2022 | 512 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1981 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2022 | 1059 | 0.040 |
Why?
| | Forecasting | 1 | 2019 | 386 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2016 | 2160 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 15504 | 0.030 |
Why?
| | Cell Lineage | 1 | 2017 | 347 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1784 | 0.030 |
Why?
| | Aged | 2 | 2025 | 23794 | 0.030 |
Why?
| | Organ Specificity | 1 | 2016 | 304 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2750 | 0.030 |
Why?
| | Cohort Studies | 1 | 2025 | 5701 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 452 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 513 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1613 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 378 | 0.030 |
Why?
| | Endothelium | 1 | 2014 | 122 | 0.030 |
Why?
| | Cytokines | 2 | 2017 | 2083 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2016 | 886 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 678 | 0.020 |
Why?
| | United States | 2 | 2019 | 14691 | 0.020 |
Why?
| | Mice, Inbred BALB C | 2 | 2005 | 1269 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1500 | 0.020 |
Why?
| | Interferon-gamma | 2 | 2005 | 788 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1177 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1772 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2472 | 0.020 |
Why?
| | Adult | 2 | 2023 | 37630 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 3264 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 10744 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 10326 | 0.020 |
Why?
| | Splenomegaly | 1 | 2005 | 15 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2005 | 200 | 0.010 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2005 | 98 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 2005 | 157 | 0.010 |
Why?
| | Interphase | 1 | 2003 | 32 | 0.010 |
Why?
| | STAT6 Transcription Factor | 1 | 2003 | 27 | 0.010 |
Why?
| | Transcription Factor AP-1 | 1 | 2003 | 92 | 0.010 |
Why?
| | CD3 Complex | 1 | 2003 | 106 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2005 | 336 | 0.010 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2003 | 123 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 2003 | 156 | 0.010 |
Why?
| | NFATC Transcription Factors | 1 | 2003 | 95 | 0.010 |
Why?
| | Solubility | 1 | 2003 | 245 | 0.010 |
Why?
| | Interleukin-12 | 1 | 2003 | 121 | 0.010 |
Why?
| | Th1 Cells | 1 | 2003 | 143 | 0.010 |
Why?
| | Acetylcysteine | 1 | 2003 | 145 | 0.010 |
Why?
| | Drug Combinations | 1 | 2003 | 343 | 0.010 |
Why?
| | Spleen | 1 | 2003 | 514 | 0.010 |
Why?
| | Down-Regulation | 1 | 2003 | 656 | 0.010 |
Why?
| | Trans-Activators | 1 | 2003 | 398 | 0.010 |
Why?
| | Up-Regulation | 1 | 2003 | 843 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2003 | 617 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 1242 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2003 | 1141 | 0.010 |
Why?
| | Liver | 1 | 2005 | 1940 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1501 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2003 | 4190 | 0.010 |
Why?
| | Transcription Factors | 1 | 2003 | 1718 | 0.010 |
Why?
|
|
Mohning's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|